Clinical Trials
14 trialsNCT04302025 2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2 Recruiting
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT01378975 2025-06-25
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02291289 2024-05-06
MODUL
Hoffmann-La Roche
Phase 2 Completed
NCT03625141 2024-04-11
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT05233332 2023-05-31
mCRC
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT05263453 2023-05-31
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT02768207 2019-08-28
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01673854 2018-07-24
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT01524978 2017-11-20
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Hoffmann-La Roche
Phase 2 Completed
NCT00949702 2017-07-25
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01586195 2017-05-25
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Genentech, Inc.
Phase 2 Terminated
NCT01286753 2016-09-07
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Hoffmann-La Roche
Phase 2 Completed